Background

Skin cutaneous melanoma (SKCM) accounts for over 75% of skin cancer-related deaths each year. EAF2, as a member of EAF family, has been found in several cancers, however, the role of EAF2 in SKCM is rarely studied.

Methods

In this study, we utilized multiple bioinformatics tools to systematically analyze the expression of EAF family and investigate the prognostic value of EAF2 in melanoma.

Results

We found both transcriptional and proteomics expression expressions of EAF2 were elevated in SKCM. Survival analysis and ROC curves showed significant diagnostic and prognostic ability of EAF2. Importantly, EAF2 expression was closely associated with the immune-infiltrating levels of B cells, CD4+ T, CD8+ T, neutrophils, macrophages and dendritic cells. Co-expression analysis showed EAF2 has a strong positive correlation with CD19, implying they may be functional partners in the immune response of SKCM.

Conclusions

In summary, our study is the first to reveal that increased expression of EAF2 is significantly correlated with tumor progression and better prognosis in SKCM patients. The role of EAF2 in SKCM demonstrated that it might be a potential and promising biomarker for the diagnosis and prediction of prognosis in patients with SKCM.

中文翻译：

---

EAF家族的系统表达分析揭示了EAF2在黑色素瘤中的重要性

背景

皮肤皮肤黑色素瘤（SKCM）每年占皮肤癌相关死亡的75％以上。EAF2作为EAF家族的一员，已在几种癌症中发现，但是，很少研究EAF2在SKCM中的作用。

方法

在这项研究中，我们利用多种生物信息学工具系统地分析了EAF家族的表达，并探讨了EAF2在黑色素瘤中的预后价值。

结果

我们发现SKF中EAF2的转录和蛋白质组学表达均升高。生存分析和ROC曲线显示了EAF2的显着诊断和预后能力。重要的是，EAF2表达与B细胞，CD4 + T，CD8 + T，嗜中性粒细胞，巨噬细胞和树突状细胞的免疫浸润水平密切相关。共表达分析表明，EAF2与CD19有很强的正相关性，这表明它们可能是SKCM免疫应答中的功能伙伴。

结论

总而言之，我们的研究首次揭示了EAF2表达增加与SKCM患者的肿瘤进展和更好的预后密切相关。EAF2在SKCM中的作用表明，它可能是诊断和预测SKCM患者预后的潜在和有前途的生物标志物。